论著

基于X染色体失活分析探讨2例X连锁智力障碍Bain型患儿的临床与遗传学特征

  • 沈子涵 ,
  • 张钏 ,
  • 郑雷 ,
  • 周秉博 ,
  • 田芯瑗 ,
  • 王玉佩 ,
  • 惠玲
展开
  • 1.甘肃省妇幼保健院/甘肃省中心医院/甘肃省出生缺陷与罕见病临床医学研究中心 (甘肃兰州 730050)
    2.甘肃中医药大学第一临床医学院 (甘肃兰州 730013)
王玉佩,电子信箱:wang_yupei_jade@163.com
惠玲,电子信箱:zyhuil@hotmail.com

收稿日期: 2025-05-16

  录用日期: 2025-09-25

  网络出版日期: 2026-03-06

基金资助

甘肃省科技计划资助项目(22YF7WA092);甘肃省科技计划资助项目(23YFFA0045);甘肃省科技计划资助项目(25YFFA057);甘肃卫生行业科研计划项目(GSWSKY2021-021);兰州市科技计划项目(2023-NQ-199)

Clinical and genetic analysis of two children with Bain type of X-linked intellectual disability caused by HNRNPH2 gene variations based on XCI analysis

  • SHEN Zihan ,
  • ZHANG Chuan ,
  • ZHENG Lei ,
  • ZHOU Bingbo ,
  • TIAN Xinyuan ,
  • WANG Yupei ,
  • HUI Ling
Expand
  • 1. Gansu Provincial Maternal and Child Health Hospital/Gansu Provincial Central Hospital / Gansu Clinical Medical Research Center of Default Defects and Rare Diseases, Lanzhou 730050, Gansu, China
    2. The First Clinical Medical School, Gansu University of Chinese Medicine, Lanzhou 730013, Gansu, China

Received date: 2025-05-16

  Accepted date: 2025-09-25

  Online published: 2026-03-06

摘要

目的 探讨2例X连锁智力障碍Bain型(MRXSB)患儿的临床表现及遗传学特征,分析X染色体失活(XCI)分析在基因型-表型关联中的作用。方法 以2023年2月和2023年11月因“全面性生长发育迟缓、智力障碍”就诊的2例女性患儿作为研究对象,收集先证者的临床资料,对先证者及其家系进行家系外显子组测序(trio-WES)及Sanger测序验证;通过XCI检测试剂盒分析甲基化敏感位点,结合毛细管电泳定量分析X染色体偏倚失活程度;应用生物信息学工具预测变异致病性。结果 2例患儿分别为11和10月龄女性,均表现为全面性生长发育迟缓、智力障碍、肌张力低下及运动里程碑缺失,其中先证者1伴有喂养困难、吞咽障碍及屏气发作。trio-WES提示2例患儿均存在HNRNPH2基因(NM_019597)c.616C>T(p.Arg206Trp)杂合变异,Sanger测序验证该变异均属新发变异。XCI分析提示先证者1与先证者2均存在X染色体偏倚失活,偏倚率分别为17.3%和14.0%。结论 本研究首次确诊了2例发病年龄<1岁的MRXSB女性患儿,通过XCI分析发现患儿X染色体均发生偏倚失活,结合患儿较早、较典型的临床表型,推测患儿XCI偏倚程度可能与表型严重性相关。XCI是女性X连锁智力障碍(XLID)临床异质性的核心调控机制,XCI联合trio-WES对女性XLID早期诊断及预后评估具有重要价值。

本文引用格式

沈子涵 , 张钏 , 郑雷 , 周秉博 , 田芯瑗 , 王玉佩 , 惠玲 . 基于X染色体失活分析探讨2例X连锁智力障碍Bain型患儿的临床与遗传学特征[J]. 临床儿科杂志, 2026 , 44(3) : 192 -201 . DOI: 10.12372/jcp.2026.25e0552

Abstract

Objective To investigate the clinical manifestations and genetic characteristics of 2 patients with intellectual disability, X-linked, syndromic, Bain type (MRXSB). Methods Two female children who visited the hospital due to "global growth and development delay and intellectual disability" in January 2023 and November 2023 were taken as the research subjects, and the clinical data of the probands were collected. Trio-whole exome sequencing (trio-WES) and Sanger sequencing verification were performed on the proband and his family. The methylation-sensitive sites were analyzed by using the XCI detection kit (XCI Filer), and the degree of X chromosome bias inactivation was quantitatively analyzed in combination with capillary electrophoresis. Bioinformatics tools were used to predict the pathogenicity of variations. Results The two children were girls aged 11 and 10 months respectively, both presenting with global growth and development delay, intellectual disability, hypotonia and absence of motor milestones. Among them, proband 1 was accompanied by feeding difficulties, dysphagia and shortness of breath symptoms. The results of trio-WES indicated that both of the two children had heterozygous variations of c.616C>T(p.Arg206Trp) in the HNRNPH2 gene (NM_019597), and Sanger sequencing verification suggested that the variations were all spontaneous variations. XCI analysis indicated that both of the two children had X chromosome bias inactivation, with bias rates of 17.3% and 14.0% respectively. Conclusions This study diagnosed for the first time two girls with MRXSB whose age of onset was<1 year old. Through XCI analysis, it was found that the X chromosomes of all the children were inactivated due to bias. Combined with the earlier and more typical clinical phenotypes of the patients, it was speculated that the degree of XCI bias in all the children might be correlated with the severity of the phenotype. XCI is the core regulatory mechanism of clinical heterogeneity in female XLID. The combination of XCI and trio-WES is of great value for the early diagnosis and prognosis evaluation of female XLID.

参考文献

[1] Bassani S, Zapata J, Gerosa L, et al. The neurobiology of X-linked intellectual disability[J]. Neuroscientist, 2013, 19(5): 541-552.
[2] Bernardo P, Cuccurullo C, Rubino M, et al. X-linked epilepsies: a narrative review[J]. IJMS, 2024, 25(7): 4110.
[3] Kim HJ, Kim NC, Wang YD, et al. Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS[J]. Nature, 2013, 495(7442): 467-473.
[4] Bain JM, Cho MT, Telegrafi A, et al. Variants in HNRNPH2 on the X Chromosome are associated with a neurodevelopmental disorder in females[J]. Am J Hum Genet, 2016, 99(3): 728-734.
[5] Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology[J]. Genet Med, 2015, 17(5): 405-424.
[6] Sun Z, Fan J, Wang Y. X-chromosome inactivation and related diseases[J]. Genet Res (Camb), 2022, 2022: 1391807.
[7] Loda A, Collombet S, Heard E. Gene regulation in time and space during X-chromosome inactivation[J]. Nat Rev Mol Cell Biol, 2022, 23(4): 231-249.
[8] Dardenne E, Polay Espinoza M, Fattet L, et al. RNA helicases DDX5 and DDX17 dynamically orchestrate transcription, miRNA, and splicing programs in cell differentiation[J]. Cell Rep, 2014, 7(6): 1900-1913.
[9] Chou MY, Rooke N, Turck CW, et al. hnRNP H is a component of a splicing enhancer complex that activates a c-src alternative exon in neuronal cells[J]. Mol Cell Biol, 1999, 19(1): 69-77.
[10] Dominguez D, Freese P, Alexis MS, et al. Sequence, structure, and context preferences of human RNA binding proteins[J]. Mol Cell, 2018, 70(5): 854-867.
[11] Varadi M, Anyango S, Deshpande M, et al. AlphaFold Protein Structure Database: massively expanding the structural coverage of protein-sequence space with high-accuracy models[J]. Nucleic Acids Res, 2022, 50(D1): D439-D444.
[12] Jumper J, Evans R, Pritzel A, et al. Highly accurate protein structure prediction with AlphaFold[J]. Nature, 2021, 596(7873): 583-589.
[13] Niu C, Zhang J, Gao F, et al. FUS-NLS/Transportin 1 complex structure provides insights into the nuclear targeting mechanism of FUS and the implications in ALS[J]. PLoS One, 2012, 7(10): e47056.
[14] Hu WF, Chahrour MH, Walsh CA. The diverse genetic landscape of neurodevelopmental disorders[J]. Annu Rev Genom Hum Genet, 2014, 15(1): 195-213.
[15] Cotton AM, Price EM, Jones MJ, et al. Landscape of DNA methylation on the X chromosome reflects CpG density, functional chromatin state and X-chromosome inactivation[J]. Hum Mol Genet, 2015, 24(6): 1528-1539.
[16] Bain JM, Thornburg O, Pan C, et al. Detailed clinical and psychological phenotype of the X-linked HNRNPH2 -related neurodevelopmental disorder[J]. Neurol Genet, 2021, 7(1): e551.
[17] Gillentine MA, Wang T, Hoekzema K, et al. Rare deleterious mutations of HNRNP genes result in shared neurodevelopmental disorders[J]. Genome Med, 2021, 13(1): 63.
[18] Kreienkamp HJ, Wagner M, Weigand H, et al. Variant-specific effects define the phenotypic spectrum of HNRNPH2-associated neurodevelopmental disorders in males[J]. Hum Genet, 2022, 141(2): 257-272.
[19] Somashekar PH, Narayanan DL, Jagadeesh S, et al. Bain type of X-linked syndromic mental retardation in a male with a pathogenic variant in HNRNPH2[J]. Am J Med Genet A, 2020, 182(1): 183-188.
[20] Harmsen S, Buchert R, Mayatepek E, et al. Bain type of X-linked syndromic mental retardation in boys[J]. Clin Genet, 2019, 95(6): 734-735.
[21] Jepsen WM, Ramsey K, Szelinger S, et al. Two additional males with X-linked, syndromic mental retardation carry de novo mutations in HNRNPH2[J]. Clin Genet, 2019, 96(2): 183-185.
[22] Lin X, Yu S, Mao H, et al. hnRNPH2 as an inhibitor of chicken MDA5-mediated type I interferon response: analysis using chicken MDA5-host interactome[J]. Front Immunol, 2020, 11: 541267.
[23] White-Brown AM, Lemire G, Ito YA, et al. A disease-causing variant in HNRNPH2 inherited from an unaffected mother with skewed X-inactivation[J]. Am J Med Genet A, 2022, 188(2): 668-671.
[24] Peron A, Novara F, La Briola F, et al. Missense variants in the Arg206 residue of HNRNPH2: further evidence of causality and expansion of the phenotype[J]. Am J Med Genet A, 2020, 182(4): 823-828.
[25] Demos M, Guella I, DeGuzman C, et al. Diagnostic yield and treatment impact of targeted exome sequencing in early-onset epilepsy[J]. Front Neurol, 2019, 10: 434.
[26] Davis TJ, Salazar R, Beenders S, et al. A prospective, longitudinal study of caregiver-reported adaptive skills and function of individuals with HNRNPH2-related neurodevelopmental disorder[J]. Adv Neurodev Disord, 2024, 8(3): 445-456.
[27] Korff A, Yang X, O'Donovan K, et al. A murine model of hnRNPH2-related neurodevelopmental disorder reveals a mechanism for genetic compensation by Hnrnph1[J]. J Clin Invest, 2023, 133(14): e160309.
[28] Kelvington BA, Abel T. hnRNPH2 gain-of-function mutations reveal therapeutic strategies and a role for RNA granules in neurodevelopmental disorders[J]. J Clin Invest, 2023, 133(14): e171499.
[29] Sun Y, Qian Y, Sun HX, et al. Case report: de novo DDX3X mutation caused intellectual disability in a female with skewed X-chromosome inactivation on the mutant allele[J]. Front Genet, 2022, 13: 999442.
[30] Kao HJ, Chiang HL, Chen HH, et al. De novo mutation and skewed X-inactivation in girl with BCAP31-related syndrome[J]. Hum Mutat, 2020, 41(10): 1775-1782.
文章导航

/